Early Use of Mulnupiravir Reduced Hospitalization, Death Among US Veterans
When both Paxlovid and Mulnupiravir were rolled out as EUA oral drugs to treat COVID-19 I accepted them clinically and placed them as antiviral options in the McCullough Protocol
One of the reasons for my early adoption was that I knew any novel drug advanced by Operation Warp Speed and endorsed by the CDC, FDA, and NIH would engage doctors who wanted to treat patients but were fearful of the stigmata associated with prescribing hydroxychloroquine or ivermectin.
In the McCullough Protocol, no drug is necessary nor sufficient, thus any oral antiviral in combination with other medications would comprise a life saving “early treatment regimen” as compared to patients who received no medications at all.
Xie et al reported from the Veterans Administration automated database and found that among US veterans of whom were 92 percent men age 70 years, 46 percent former smokers, 63 percent vaxxed and boosted, that early use of the SARS-CoV-2 polymerase inhibitor, mulnupiravir, especially if started on Day 1, was associated with reduced risk of post-acute sequalae, hospitalization, and death after acute COVID-19.
Of note, slightly more patients who received mulnupiravir had natural immunity (18 percent) and more received concurrent corticosteroids (14 percent). The authors did not account for other ambulatory drugs in the McCullough Protocol but I anticipate that mulnupiravir was associated with more extensive use of multidrug therapy shown to reduce hospitalization and death.
In summary, we use non-randomized analyses such as this not to make therapeutic claims on a specific drug, but to analyze overall patterns of care and in this case be reassured that early mulnupiravir as part of a multidrug regimen was associated with achieving the over-arching goal of reducing hospitalization and death.
The only shortcoming is that not all high risk patients were given a chance with home therapy to survive free of these two outcomes
See more here substack.com
Header image: Pharmaceutical Technology
Please Donate Below To Support Our Ongoing Work To Expose The Lies About Covid 19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.